The estimated Net Worth of Tarek Sahmoud is at least $48 Thousand dollars as of 16 August 2022. Dr Sahmoud owns over 10,000 units of Centrexion Therapeutics stock worth over $21,400 and over the last 2 years he sold CNTX stock worth over $0. In addition, he makes $26,610 as Chief Medical Officer at Centrexion Therapeutics.
Dr has made over 1 trades of the Centrexion Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CNTX stock worth $19,500 on 16 August 2022.
The largest trade he's ever made was buying 10,000 units of Centrexion Therapeutics stock on 16 August 2022 worth over $19,500. On average, Dr trades about 5,000 units every 0 days since 2022. As of 16 August 2022 he still owns at least 10,000 units of Centrexion Therapeutics stock.
You can see the complete history of Dr Sahmoud stock trades at the bottom of the page.
Dr. Tarek Sahmoud M.D., Ph.D. is the Chief Medical Officer at Centrexion Therapeutics.
As the Chief Medical Officer of Centrexion Therapeutics, the total compensation of Dr D at Centrexion Therapeutics is $26,610. There are 3 executives at Centrexion Therapeutics getting paid more, with Jennifer Minai-Azary having the highest compensation of $404,331.
Dr D is 60, he's been the Chief Medical Officer of Centrexion Therapeutics since . There are 2 older and 3 younger executives at Centrexion Therapeutics. The oldest executive at Centrexion Therapeutics Corporation is Dr. Evan G. Dick, 69, who is the Sr. VP of R&D.
Tarek's mailing address filed with the SEC is 2001 MARKET STREET, SUITE 3915, UNIT #15, PHILADELPHIA, PA, 19103.
Over the last 3 years, insiders at Centrexion Therapeutics have traded over $0 worth of Centrexion Therapeutics stock and bought 152,118 units worth $245,330 . The most active insiders traders include Richard J Berman, Martin A. Lehr, and Linda West. On average, Centrexion Therapeutics executives and independent directors trade stock every 32 days with the average trade being worth of $21,702. The most recent stock trade was executed by Martin A. Lehr on 21 February 2023, trading 5,823 units of CNTX stock currently worth $4,891.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Centrexion Therapeutics executives and other stock owners filed with the SEC include: